banner

Blog back to homepage

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800.

The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976.

The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

The Dow is up more than 20% so far this year. The S&P 500, despite today”s downward performance, has soared more than 25% in 2013. The NASDAQ was on the verge of a milestone, too, nearing 4,000, a level it hasn”t hit since September 2000 — just months after the tech market collapsed.

Boeing shares rose Monday after the aircraft maker said it sold more than $95 billion U.S. of its new 777X at the Dubai air show. Boeing said it was a record launch for a new aircraft and was far more than analysts had been forecasting. Boeing has been the biggest gainer in the Dow this year, soaring more than 85%.

Boeing has also been the power behind the Dow”s rise from 15,000 to 16,000, rising 48% during the six-month period.


Tesla shares dropped 9% Monday, extending the slide that began last month. A series of battery fires have triggered a nearly 40% plunge in shares of Tesla since early October. Still, the stock is up almost 270% so far this year.

Sony shares rose after the company said it sold more than one million units of its new PlayStation 4 gaming console in the first 24 hours since the game console went on sale early Friday. The game system is Sony”s first in seven years and is going head-to-head with Microsoft”s upcoming Xbox One this holiday season. Shares of Microsoft slipped.

While stocks continued to soar, so did Bitcoin. The price of the digital currency touched an all-time high above $600 earlier Monday, up almost 20% from Friday”s closing price of $528.32.

Since the start of October, the price of Bitcoin has more than quadrupled in value.

The latest surge has been fueled by the interest of new investors, especially those in China, who are becoming increasingly optimistic about the digital currency”s potential growth.

Prices for 10-year U.S. Treasuries were higher, lowering yields to 2.68% from Friday”s 2.71%. Treasury prices and yields move in opposite directions.

Oil prices stumbled 88 cents to $92.96 U.S. a barrel.

Gold prices shed $15.20 to $1,272.20 U.S. an ounce.

Dow Jones Industrial Average (DJIA) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be reversing from a recent downtrend after hitting highs in October.





Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst’s lead candidate, Firdapse™ for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal Phase 3 trial and recently received “Breakthrough Therapy Designation” from the U.S. Food and Drug Administration (FDA). In 2012, Catalyst licensed Firdapse™ from BioMarin and Catalyst assumed management of the Phase 3 pivotal trial, initiated by BioMarin. Firdapse™ is the first and only European approved drug for symptomatic treatment in adults with LEMS.

Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette Syndrome. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted EU orphan medicinal product designation for the treatment of West Syndrome by the European Commission.

Catalyst Pharmaceutical Partners Inc. (CPRX) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel.


EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. EnteroMedics’ proprietary technology, VBLOC® vagal blocking therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. VBLOC allows people with obesity to take a positive path towards weight loss, addressing the lifelong challenge of obesity and its comorbidities without sacrificing wellbeing or comfort. EnteroMedics’ Maestro Rechargeable System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.

NXT-ID Authentication Using Face and Voice Recognition NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and identity product that is being developed by Shelton, Connecticutt-based NXT-ID, Inc. (OTCQB:NXTD).

NXT-ID was founded by former senior management at Technest Holidings and its subsidiary, Genex Technologies, industry-leading companies in the field of advanced imaging, including 3D and 360-degree technologies. NXT-ID has licensed these companies’ technologies, as well as technologies from 3D-imaging expert Geometrix. Utilizing these technologies with their own intellectual property, NXT-ID is launching MobileBio, a technology that secures consumers’ mobile platforms through authentication and encryption. As the trend continues to move towards mobile transactions, there is a great need for advanced solutions to protect users’ and institutions’ information more effectively than the inherently insecure standards of payment today. MobileBio is the cornerstone of NXT-ID’s end-to-end solutions to bridge the gap.

The company has developed Biocloud, a cloud-based biometric identify authentication solution for consumer applications and corporate security. The company’s MobileBio Voicematch platform can be bootstrapped to several platforms, such as smartphones, tablets and computers, to embed additional security via voice recognition biometrics to ensure the identity of a user before allowing access to countless applications. Voicematch is forecast to be available in the first quarter of 2014. Along the same lines, MobileBio Facematch employs modular facial recognition to devices for superior authentication and encryption. Several configurations are possible, including hosting the technology on a device or remotely in the cloud by marrying Facematch with Biocloud. According to NXT-ID, Facematch will soon be available in an app for iPhone and Android systems.



After Thursday’s closing bell, NXT-ID announced that it took the next step with its next-generation digital wallet, called the “Wocket.” The Wocket is being designed to reduce the number of cards in a person’s wallet while supporting essentially every payment method used today at retailers, such as magnetic stripe, barcodes, etc. all from a secure digital vault. The company said that it has successfully ported its MobileBio voicematch algorithm to the Wocket, which brings the product one move closer to commercialization.

“We are pleased with the continued development of the Wocket™,” says David Tunnell, CTO of NXT-ID. “Our approach eliminates the need for passwords by authenticating identity in a natural way for users. With Voicematch™, users can simply ask for a user-defined name of a card and the Wocket™ then automatically programs the NXTCard with the card of their choice.”

A lot of noise has been made recently about improving security on devices of all types. Apple (Nasdaq:AAPL) was even criticized for not including their thumbprint technology on the latest generation of iPhones 5C’s to prevent unauthorized use. While thumbprint technology is certainly a more advanced security feature and will be welcomed by the masses, what NXT-ID is taking things to the next level with voice and facial recognition. In short (and layman’s terms), this is some pretty cool stuff.

NXT-ID is an early-stage company that just went public in August via an S-1 registration, but interest seems to remain strong with shares climbing from initially around $1.50 to as high as $6.00 before pulling back to current levels around $3.50. As the products start rolling-out to the public, even more investors (and other companies) may start taking note of this upstart and the cutting-edge technology it possesses. Proper due diligence is, as always, encouraged.

NXT-ID, Inc. (NXTD) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

Dow Not Tired of Making New Record Highs(0)

The Dow Jones Industrials will have to wait till at least next week to mount the lofty heights of 16,000 points, but both the Dow and the S&P did end the day at record highs.

The Dow Jones Industrials was up 85.48 points from yesterday”s all-time high, to close at 15,961.70

The S&P 500 index moved up 7.56 points from its all-time peak to 1,798.18. The NASDAQ strengthened 13.23 points to 3,985.97

The Dow is closing in on 16,000, while the S&P 500 is inching toward 1,800, both of which would be reached for the first time. The tech-heavy NASDAQ is nearing 4,000, a level not seen since September 2000, just after the collapse of the dot-com bubble.

Some believe stocks can continue moving higher in the short run as investors who have sat out the rally so far rush to get in before the party”s over. Plus, stocks are still trading at compelling valuations, compared with many other assets. Bulls also say that the market surge is justified by improving economic conditions and record corporate profits.

Shares of J.C. Penney rose on news that several hedge funds, including Appaloosa Management, have invested in the ailing retailer.

The stock is the worst performer in the S&P 500 this year, but it has rallied lately and will report its latest quarterly results next week.

U.S.-listed shares of voxeljet, a German manufacturer of 3D printers, jumped 6%. The company raised its outlook for the year after revenue surged 77% in the third quarter. Earnings more than tripled in the quarter.

Organovo, a company that produces human tissues using 3-D bioprinting technology, ended flat after surging 10% in early trading. The stock is up nearly 400% so far this year.



Shares in Exxon Mobil were higher after it was revealed that Warren Buffett”s Berkshire Hathaway made a big bet on the company, buying roughly 40 million Exxon shares — worth $3.74 billion U.S. at Thursday”s closing price.

Government-sponsored mortgage giants Fannie Mae and Freddie Mac both surged after activist shareholder Bill Ackman disclosed in a regulatory filing that his firm, Pershing Square, bought just under a 10% stake in each firm.

And there was another hot IPO Friday. Zulily, a daily deals site that focuses on apparel for babies, kids and moms, surged nearly 70% in its debut.

Prices for 10-year U.S. Treasuries were lower, raising yields to 2.71% from Thursday”s 2.70%. Treasury prices and yields move in opposite directions.

Oil prices were unchanged at $93.76 U.S. a barrel.

Gold prices gained 90 cents to $1,287.20 U.S. an ounce.

Dow Jones Industrial Average (DJIA) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

Athersys Stock Chart Analysis Video(0)

After hitting highs above $2 in October, the Athersys (NASDAQ: ATHX) chart is back down on a support level around $1.60. A move upward on Wednesday starting turning trend and momentum indicators, dropping hints that the chart could be ready to go through an upswing again off the support point.



Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem(R) cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft versus host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.

Athersys (ATHX) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

Wall Street Rises Again(0)

Stocks ended modestly higher Thursday after Federal Reserve chair nominee Janet Yellen indicated in a Senate hearing that she will continue to support the economy with stimulus measures.

Investors were encouraged and sent the Dow Jones Industrial Average and S&P 500 to new records.

The Dow was up 54.59 points to 15,876.20

The S&P 500 index moved up 8.62 points to 1,790.62. The Dow is now just 1% from hitting 16,000, while the S&P 500 is less than 1% from 1,800.

The NASDAQ crept up 7.17 points to 3,972.74, as a drop in Cisco shares weighed on the tech-heavy index. Even so, the NASDAQ is now at its highest level since September 2000 and is less than 1% from 4,000.

Cisco shares tumbled more than 10% after the company reported weak sales for the fiscal first quarter and issued a weak outlook for the current quarter, too.

Cisco CEO John Chambers blamed a “hard to read” economic environment, adding that the U.S. government shutdown increased the “lack of confidence among business leaders.”

Wal-Mart reported better-than-expected earnings, though the retailer missed on revenue and reported a slight decline in same-store sales in the U.S. Shares of department store chain Kohl”s plunged following poor results and a weak outlook.

The bad news from these two retailers comes one day after Macy”s ignited a retail rally thanks to its strong sales and guidance.


One observer noted that while Macy”s and even Michael Kors are still attracting shoppers, the economy otherwise is forcing consumers to keep a tight grip on their wallets. Though thanks to the ongoing housing recovery, home improvement giants Lowe”s and Home Depot are still improving.

Viacom reported a gain in quarterly revenue, driven by sales in media networks and filmed entertainment, and double-digit gains in net earnings.

Investors have been looking for clues as to when the Fed may begin scaling back its bond purchases. There has been speculation that the so-called tapering could begin as early as next month.

But during her question and answer session on Capitol Hill, Yellen said that the bond-buying program could still help the economy.

“It”s important not to remove support, especially when the recovery is fragile,” she said. “I believe it could be costly to withdraw accommodation or to fail to provide adequate accommodation.”

The comments appear to have convinced investors that Yellen would continue the Fed”s current $85-billion-U.S.-per-month bond-buying program for the next few months. The program — also known as quantitative easing or ”QE” — has helped spur stocks by pumping markets with extra cash.

Prices for 10-year U.S. Treasuries regained ground, lowering yields to 2.70% from Wednesday”s 2.72%. Treasury prices and yields move in opposite directions.

Oil prices faded 10 cents to $93.78 U.S. a barrel.

Gold prices hiked $18.30 to $1,286.70 U.S. an ounce.

Dow Jones Industrial Average (DJIA) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

Gold Production and Revenue Surges in Q3 for B2Gold(0)

Gold prices rebounded on Wednesday ahead of the confirmation hearing of Federal Reserve Chairman nominee Janet Yellen. President Barack Obama last month nominated Yellen, currently the vice chairman of the central bank, as the successor to current chairman Ben Bernanke. Because Yellen is viewed by most as having a more dovish stance on quantitative easing than Bernanke, analysts see her as being supportive of gold prices, although prices have been tossed to-and-fro on speculation of when tapering will begin on the Fed’s large monetary easing policy. Commentary from Yellen released yesterday did little to provide a timeframe, with Yellen just offering that the economy has made “good progress,” but is still “far short” of where it needs to be. With that, and in combination with a technical bounce, gold rallied more than 1 percent and is starting Thursday off with more upward pressure.

The mining faithful would like nothing more than to see gold break its bearish trend, including Vancouver-based B2Gold Corp. (TSX:BTO) (NYSE MKT:BTG), who early Thursday morning released its earnings report for the third quarter showing a big jump in production. B2Gold has three operating mines, the Masbate Mine in the Philippines and the Libertad Mine and the El Limon Mine in Nicaragua. Two other mines, Otjikoto in Nambia and Gramalote in Columbia, are expected to be in full production in 2015 and 2018, respectively.

Incidentally, Typhoon Haiyan, which leveled parts of the Philippines on November 8, had no material impact on the Masbate Mine. B2Gold said it has pledged $1 million for relief and reconstruction efforts in the Philippines.

On October 28, B2Gold said that it was buying Volta Resources Inc. (TSX:VTR) for about $63 million in an all-share transaction. Upon customary approvals, the acquisition will give the company an 81-percent interest in the advanced-stage Kiaka gold project in Burkina Faso, Africa and a 100-percent interest in two nearby gold exploration projects. A Pre-Feasibility Study on the Kiaka project showed an average annual production rate of approximately 340,000 ounces of gold over a 10-year mine life.



In the quarter ended September 30, B2Gold reported revenue of $128.7 million, up by 108 percent to $67.0 million in the third quarter of 2012. During the latest quarter, B2Gold sold 93,429 ounces of gold at an average price of $1,378 per ounce, compared to 39,668 ounces at an average of $1,691 per ounce a year earlier. Net income totaled $7.9 million, or 1 cent per share, compared to $14.5 million, or 4 cents per share, in Q3 2012. Adjusted income, which strips out one-time items, was $12.4 million, or 2 cents per share, versus $19.7 million, or 5 cents per share, in last year’s quarter.

Profits were trimmed by higher administrative costs, increased realized derivative losses, higher interest expenses and the company paying more income taxes than a year earlier.

B2Gold produced a record 98,992 ounces of gold, a 135-percent improvement from the year prior quarter. The majority of the increase was attributable to the acquisition of the Masbate Mine in January. Consolidated operating cash costs were $653 per ounce of gold. That was well below budgeted operating cash costs of $725 per ounce and $732 per ounce reported in the second quarter. All-in-sustaining costs were $995 per ounce.

For the first nine months of 2013, B2Gold has produced 274,710 ounces of gold. Revenue has risen $218.0 million over the same period in 2012 to $406.2 million. Adjusted net profit for the period is $60.0 million, or 10 cents per share.

As of September 30, the company had $283.7 million in cash and cash equivalents, up from $95.7 million at the end of June.

Looking ahead, B2Gold reiterated its guidance for a fifth consecutive year of increased gold production with production expected in the range of 360,000 to 380,000 ounces. Consolidated cash operating costs are targeted between $675 and $690 per ounce. For 2014, the company sees production increasing to 395,000 to 420,000 ounces at a consolidated cash operating cost of $680 to $705 per ounce.

US-listed shares of BTO closed Thursday at $2.33 for gains of 4.95 percent to add to a small gain on Wednesday.

B2Gold Corp. (BTG) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

Hearing Date Set in Blue Calypso Lawsuit Against LivingSocial Hearing Date Set in Blue Calypso Lawsuit Against LivingSocial(0)

Blue Calypso Inc. (OTCBB: BCYP), an innovator in digital social advertising, mobile content syndication, and analytics, recently announced a Markman hearing set for August 27, 2013 in its patent infringement case against LivingSocial. Findings from this hearing may encourage settlements or provide insight into the likelihood of a particular outcome.

With the success seen by companies like Vringo Inc. (AMEX: VRNG) in their lawsuit against AOL Inc. (NYSE: AOL) and VirnetX (ASE: VHC) in their case against Apple Inc. (NASDAQ: AAPL), Blue Calypso is a stock worth watching closely as this date approaches. Successful litigation could set the stage for similar outcomes against many other companies in the space.

“We believe that there may be a significant and growing number of companies infringing our patents. We intend to pursue every legal remedy at our disposal to protect our core intellectual property and have initially targeted companies that are leaders in various business segments where we compete. A successful outcome would prove out the value of our intellectual property portfolio and validate the market potential of Blue Calypso’s technologies,” said Bill Ogle, Chairman and Chief Executive Officer of Blue Calypso in the recent press release.



Companies in this situation, depending on the results of the Markman hearing, will often settle out of court rather than endure the time and expense of extended litigation. Terms of these settlements often include licensing agreements that allow the company being sued to continue using the technology in exchange for ongoing fees. In this case against LivingSocial, as well as the pending cases against Groupon, Foursquare, Yelp, IZEA and MyLikes, Blue Calypso shareholders would likely benefit greatly from such an arrangement.

“We are confident that Claim Construction Hearings will be scheduled for each of these cases toward the end of 2013, with full jury trials expected in mid-2014, if licensing agreements or other remediation is not achieved prior to litigation,” added Mr. Ogle in the press release, when discussing the actions against other companies in the space.

These cases are being represented by recognized leaders in patent protection and litigation, including Farney Daniels P.C. in its claim against LivingSocial, and Fish & Richardson P.C. in its claims against Groupon, Foursquare, Yelp, IZEA and MyLikes.

Blue Calypso (BCYP) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

Digital Development Group Partners with Hollywood Bad Boy Charlie Sheen Digital Development Group Partners with Hollywood Bad Boy Charlie Sheen(0)

One might think that celebrity endorsements would be fantastic for the share price of a small or microcap company. After all, famous and successful athletes or movie stars have a stack of cash to invest and the connections to help accelerate business developments. Oddly, though, it doesn’t seem to have a great deal of impact. Even sports legends Shaquille O’Neal and Reggie Jackson being onboard as both investors and brand ambassadors to Soupman, inc. (OTCQB: SOUP) haven’t lifted shares. In fact, shares actually slipped lower after announcing Shaq, one of the biggest names in basketball history and a promotional wizard, in late 2011.

Surely hoping that the announcement of a new star partner will have a more beneficial impact on market valuation is Digital Development Group Corp. (OTCBB: DIDG) with Wednesday evening’s report that actor Charlie Sheen has joined the team. The Hollywood-based company is involved in acquisition and distribution of Over the Top, or “OTT,” television content.



OTT content is, in short, the broadband delivery of video or audio by a third party (meaning that the Internet service provider is not involved in the control or distribution of the content) that is accessible through multiple internet-connected mediums. It is steadily gaining traction as consumers continue to utilize more mobile devices, smart TVs, connected DVD players, game consoles and devices like Roku to meet their demands to control what they watch free of constraints of traditional cable programming packages and, often times, commercials. Household names in the OTT industry include Netflix (NASDAQ: NFLX) and Hulu.

Obviously, big-budget companies like Netflix and Hulu tailor their business towards distribution of mainstream programs and movies, but smaller companies like DigiDev, as it is often called, are initially focused on creating original content for its growing library of material. For a small fee, the company currently offers access to collections through channels such as its “Sci-Fi Station” with cult classics in horror, science fiction, etc. and “Synapse Films,” which contains a wide array of “features, documentaries and clips…be it weird, offbeat, cult, sexy, exploitation, B movies, or other strange and unusual titles,” to name a few.

Future offerings include channels featuring people like Kato Kaelin, made famous as a witness in the O.J. Simpson murder trial, former porn star (and vice presidential candidate) Marilyn Chambers, and now Charlie Sheen.

Sheen, the son of Hollywood icon Martin Sheen and brother of actor Emilio Estevez, has made a positive name for himself as a star in blockbuster movies such as Platoon and Wall Street and TV show Two and a Half Men, but also has had his personal life criticized with reports of alcohol and drug abuse as well as alleged domestic violence.

Describing his company as “misfits of TV,” DigiDev president Joe Q. Bretz, says that he has been working with Sheen for “quite some time” to ink the new partnership. Bretz explained that “misfits change the world, and we intend on creating something alongside Charlie that will be historical.”

“A long time ago on a movie set far, far away, a character I once played said, ‘life all comes down to a few moments, and this is one of them,’” commented Sheen in the corporate statement. “DigiDev is one of these moments. For years I have longed for a home and an outlet for the tsunami that is my brain. Batten down the Forbes hatches; I hope DigiDev can hold its breath for a long time.”

Sheen will serve as curator of DigiDev’s channels and as an advisor for special content acquisitions, according to the company. No filings with the SEC have been made as of the time of this writing to sift through for more details of the contract.

From the investor side, traders will be watching on Thursday to see if the news can make a splash. Shares of DIDG have been on the slide since it began trading in April 2012 around $1.30 per share, closing Wednesday at 8.5 cents, for gains of 10.4 percent on the day.

Shares had sunk as low as 5 cents in January, before spiking to 20.5 cents about two weeks later. Will this be the kick it needs for the stock to identify the nickel mark as a true bottom and start a new uptrend? Well, only time will deliver that answer, but this is an interesting development for fans of DigiDev and Hollywood’s bad boy. Proper due diligence is, as always, encouraged.

Article submitted by AllPennyStocks.com

Digital Development Group (DIDG) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.


Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.